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Summary A total of 8,427 women with breast cancer with height and weight measured prior to the diagnosis
were followed up for on average 4.3 years. 2,383 women died from breast cancer and 430 from other causes.
Among women diagnosed without any metastasis (stage I) the death rate was 1.70 times higher for those
belonging to the highest quintile of body mass with respect to age compared to those in the lowest quintile.
For patients with involved lymph nodes at diagnosis (stage II) the death rate was 1.42 times higher.
Overweight was not a prognostic factor for stages III and IV patients. The prognostic effect of body mass in
stages I and II was mainly connected to those in the highest quintile and was found for women in pre- as well
as post-menopausal age. The effect did not depend on the length of time between measurement and diagnosis.
Height was not found to be of prognostic relevance. The idea of the feasibility of a dietary trial in terms of the
minimum trial size is given.
In a recent study of the relation between height and weight
and breast cancer morbidity (Tretli, 1989), height was found
to be a risk factor independent of age. Overweight was a risk
factor in the post-menopausal age-group while it appeared to
protect against breast cancer in the pre-menopausal age-
group. When stage I and stages II-IV were used as follow-
up endpoints, a negative and positive association, respec-
tively, with overweight was found indicating that overweight
reflects enhanced growth. A reasonable extension of this
study was to use the same series to look at premorbid height
and weight as possible prognostic factors for the outcome of
the disease. Most studies on the subject have shown that
overweight aggravates the prognosis of breast cancer patients
(Rose & Boyar, 1986). Height, however, has not been shown
to be a prognostic factor (De Waard, 1986).
The size of our series is much greater than that of previous
studies. This allows an analysis within each of the four stages
of the disease. In this study we pay special attention to the
fact that overweight ought to be considered relative to the
person's age at time of measurement and we look for feasible
weight groups with respect to possible dietary intervention
trials.
Materials and methods
Between 1963 and 1975 The National Mass Radiography
Service measured the height and weight of all participants in
a nationwide tuberculosis screening programme. The survey
included all inhabitants over 15 years of age in 17 of 19
counties in Norway. The counties Oslo and Buskerud, which
were not included, comprise 17.5% of the population of
Norway. The study is based on this survey but restricted to
the age-group 30-69 years at time of height and weight
measurement. Altogether 567,333 women attended the
screening in this age-group. The attendance rate was 85%
with a range from 82% to 89% in the eight five-year age-
groups. These women were followed until the end of 1981
through the population-based Norwegian Cancer Registry.
8,427 new cases of breast cancer were diagnosed and of these
97% were histologically verified. All these cases were fol-
lowed up with respect to death in the same period by means
of information from the Central Bureau of Statistics. The
underlying cause of death on the death certificate was used.
This linkage was made possible by the national system of
personal identification numbers.
Height was measured to the nearest centimetre and weight
to the nearest half kilogram on regularly calibrated scales.
The persons were asked to undress the upper body because
of the X-ray examination and to take off their shoes. A small
number of measurements were made under special circum-
stances (e.g. pregnancy, kyphosis, wearing shoes etc.) and
were therefore excluded.
The staging procedure which is used at the Cancer Regis-
try of Norway, and thereby in this study, is based on clinical
forms and histopathology reports. For nearly all breast
cancer patients in this study, the breast was removed with
varying degree of axillary lymph node toilette. Based on
clinical as well as macro- and microscopical informations
about extension of the primary tumour on the pathological
forms, stage I, II or III was stated. Stage IV was stated if
information from the clinical reports in a period of four
months from the date of diagnosis, indicated distant metas-
tases. The definition of stage at diagnosis used was: stage I,
tumours of all sizes confined to the breast (except cases
belonging to stage III); stage II, tumour in the breast with
metastases to the axillary lymph nodes; stage III, tumour in
the breast with direct extension to the skin or chest wall (may
or may not have axillary lymph node metastases); stage IV,
tumour in the breast with distant metastases.
Of a total of 8,427 breast cancer cases 4,019 cases (47.7%)
were diagnosed in stage I, 2,808 cases (33.3%) in stage II,
464 cases (5.5%) in stage III and 636 cases (7.5%) in stage
IV. For 500 cases the stage was unknown.
As a measure of obesity we have used Quetelet's index
which is defined as weight divided by the height squared.
This index has been shown to be strongly correlated to
weight and almost uncorrelated to height (Benn, 1971). In
our series weight divided by height raised to the power of 1.8
would have been uncorrelated to height. However, the
change in results by using 1.8 instead of 2.0 as the exponent
is so small that we have chosen to use Quetelet's index to
make our results comparable to those of previous studies.
A special examination of the association between size of
the tumour and Quetelet's index was carried out on a sample
of patients treated at the Norwegian Radium Hospital. Fifty-
five patients diagnosed in stage I belonging to the first quin-
tile of Quetelet's index and 53 stage I patients in the fifth
quintile were randomly selected. Information on the tumour
size of these patients was collected from the hospital records
where the TNM classification was used (UICC, 1968).
Statistical methods
Cox's (1972) regression model is used in the survival analysis.
Death from causes other than breast cancer was treated as
censoring in the same manner as the end of follow-up period.
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We felt that both height and Quetelet's index should be
related to the woman's age, height because of a strong
birth-cohort effect (Figure la) and Quetelet's index for
biological reasons. The quintile groups for height and
Quetelet's index were therefore defined within each of the 8
five-years age-groups at time of measurement for the total
series of 567,333 women. The quintile-groups are hence
specific to age as shown in Figure la,b.
The model used to estimate the intensity of death from
breast cancer among the cases at time t (t denotes the time
since diagnosis in months), is described by:
l(t;oj,nk,01)= A(t) exp(aj + nk + 0) j = 2,3; k = 2,..,5; 1 = 2,..,5
where X0(t) is the baseline intensity for a patient who belongs
to age-group 30-49 years at time of diagnosis, first quintile
of relative height and first quintile of relative Quetelet's
index. xj is the age-effect categorised into 3 age-groups
30-49, 50-64, 65 + years, nk is the relative height-effect
categorised into quintile groups and 01 is the effect of
Quetelet's index categorised into quintile groups. This means
that we, for example, may think of exp(@3) as a relative risk
due to the fact that a person's age is above 65 years at time
of diagnosis instead of being 30-49 years.
The survival curve for a patient belonging to age-group j
at time of diagnosis, quintile-group k of height and quintile-
group I of Quetelet's index, is given by:
S(t;aj,nk,O1) = exp [- t A0(s)ds * exp(@j + nk + 0k)]
j= 2,3; k = 2,..,5; I= 2,..,5.
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Figure 1 Age-specific limits for grouping height (a) and
Quetelet's index (b) into quintiles (approximately) in the total
series of 567,333 women. Ql, Q2, .., Q5 denotes the quintile
number.
The analysis is done within subgroups defined by the stage of
the disease at time of diagnosis. The statistical package
BMDP (1985) was used in the analysis. The adequacy of the
proportional hazards assumptions in the regression models
were checked by In(-ln)-plots from stratified analysis for the
variables included as covariates (Kalbfleisch & Prentice,
1980) and the assumptions were accepted.
The estimations of the sample size of a possible interven-
tion trial are based on log rank statistics (Freedman, 1982)
with a significance level of 0.05 and a statistical power of
0.80 of detecting a medically significant effect on the survival.
In this case the effect corresponds to the difference between
the survival rate of those in the fifth quintile and those in the
fourth quintile of Quetelet's index. All computations are
based on the women who belong to the fifth quintile of
Quetelet's index and who are 30-75 years of age.
Results
After an average follow-up period of 4.3 years (range: 0-18
years) 5,614 out of 8,427 breast cancer patients (66.6%) were
still alive, 2,383 (28.3%) died from breast cancer and 430
(5.1%) died from other diseases. The difference between 430
and the expected number of 507.8 based on death rates of the
total population by age and year of birth, is statistically
significant. Looking into subdiagnosis the differences between
observed and expected number of deaths are small. The
largest deviance is seen for 'other diseases than cancer and
cardiovascular diseases' (65 deaths observed versus 95.7
expected).
Table I presents the results of Cox's regression analysis
conducted within each of the four stages of the disease at
time of diagnosis. The age at diagnosis is a prognostic factor
for patients diagnosed in stages I or II but not for patients in
stages III or IV.
Height is known to be a risk factor for breast cancer, but
not a prognostic factor (De Waard, 1986). We found no
prognostic effect of height in this study.
Quetelet's index appears to be a prognostic factor for
breast cancer diagnosed in stage I or II of the disease but not
for stages III and IV. Table I shows that the prognostic effect
of the relative Quetelet's index is mainly connected to the
highest quintile of the distribution. This means that there is a
Table I The relative risk ofdying from breast cancer by categories ofage at diagnosis, relative height and
Quetelet's index within the four stages of breast cancer
Stage I Stage II Stage III Stage IV
Relative risk Relative risk Relative risk Relative risk
Age at 30-49 1.00 1.00 1.00 1.00
diagnosis 50-64 1.32 (1.05, 1.66) 1.32 (1.13, 1.53) 1.05 (0.69, 1.59) 1.21 (0.93, 1.57)
(years) 65 + 1.73 (1.36, 2.21) 1.41 (1.19, 1.68) 1.07 (0.69, 1.66) 1.15 (0.86, 1.52)
I.Quintile 1.00 1.00 1.00 1.00
Relative 2.Quintile 1.03 (0.78, 1.35) 0.97 (0.81, 1.17) 0.78 (0.52, 1.19) 0.96 (0.72, 1.27)
height 3.Quintile 1.10 (0.84, 1.43) 0.98 (0.81, 1.17) 0.76 (0.50, 1.17) 1.05 (0.81, 1.36) 4.Quintile 0.89 (0.66, 1.20) 0.96 (0.79, 1.17) 0.93 (0.58, 1.49) 0.95 (0.71, 1.27)
5.Quintile 1.29 (0.99, 1.68) 0.93 (0.77, 1.13) 0.96 (0.62, 1.49) 0.93 (0.71, 1.23)
I.Quintile 1.00 1.00 1.00 1.00
Relative 2.Quintile 1.17 (0.87, 1.56) 1.12 (0.90, 1.38) 0.85 (0.53, 1.35) 0.88 (0.65, 1.20)
Quetelet's 3.Quintile 1.32 (1.00, 1.73) 1.17 (0.96, 1.38) 0.79 (0.51, 1.24) 0.70 (0.52, 0.96)
Index 4.Quintile 1.38 (1.04, 1.83) 1.10 (0.90, 1.35) 0.94 (0.61, 1.43) 0.89 (0.67, 1.18)
5.Quintile 1.70 (1.29, 2.25) 1.42 (1.17, 1.73) 0.97 (0.63, 1.47) 1.09 (0.82, 1.45)
95% confidence intervals are given in parentheses. Study group: All breast cancer cases.HEIGHT-WEIGHT AND SURVIVAL OF BREAST CANCER 301
significant excess risk of dying if the Quetelet's index value
in the age-group 30-34 years is above 2.55 g cm-2 (for exam-
ple: height = 160 cm and weight = 65.2 kg) and above 3.10 g
cm 2 (for example: height = 160 cm and weight = 79.4 kg) in
the age-group 65-69 years. Although the relative risk of
dying between highest and lowest quintile of Quetelet's index
is higher in stage I than in stage II, the absolute prognostic
effect is greater in stage II. The visualisation of this is seen in
Figure 2a,b,c. The five year survival of patients in stage I is,
in the three age-groups 30-49, 50-64 and above 65 years
respectively 93%, 90% and 87% in the lowest quintile and
88%, 84% and 79% in the higest quintile. The corresponding
figures for patients diagnosed in stage II are: 70%, 62% and
60% in the lowest quintile and 60%, 51% and 48% in the
highest quintile.
The height and weight measurement is premorbid which in
this connection means that the height and weight measure-
ment was carried out before the breast cancer diagnosis. We
have therefore examined whether the result shown in Table I
was influenced by the time elapsed between height and weight
measurement and diagnosis. This was done by running a
sub-group analysis by dividing the time-span into three
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groups: 0-12 months, 13-59 months and 60 + months. The
result (not demonstrated) shows no significant impact of this
variable.
It has been claimed that the prognostic effect ofoverweight
valid is for post-menopausal women only. A sub-group
analysis by age does not confirm this point of view. The
estimated prognostic effect of Quetelet's index was similar to
the result shown in Table I for each of the three age-groups
decribed in the model.
We also carried out a survival analysis when only the time
interval from 24 months after diagnosis is taken into
account. This implies that we are 'excluding' events in the
active period of treatment. The result reveals that the prog-
nostic effect ofQuetelet's index in the fifth quintile becomes a
little stronger (not shown).
Table II shows a significant positive association between
tumour size and Quetelet's index (P = 0.015) obtained in the
separate study. This study made it possible to check the
quality of the Cancer Registry's staging of the patients (used
in the main study) versus the clinical notes. The comparison
reveals complete accordance.
We have made some computations to get an idea of the
size of an intervention trial organised as a randomised two-
group study among women belonging to the fifth quintile of
the Quetelet's index. Table III shows the number needed and
the minimim size of the background breast cancer population
for four trial designs.
Discussion
We found that death from other diseases was less frequent in
breast cancer cases than in the general population when age
and year of birth are taken into account. This may be
explained by the fact that high socio-economic status is
positively associated with breast cancer (Rimpela & Pukkala,
1987) and negatively associated with most other diseases than
breast cancer (Borgan & Kristofersen, 1986). Overweight per-
sons have a higher mortality in general and especially an
excess mortality from cerebrovascular disease and diabetes
(Waaler, 1984). The observed mortality from cerebrovascular
disease and 'other disease' (including diabetes) was 137 ver-
sus 179.3 cases expected. It is unlikely that this difference,
taking into account that 2,383 patients died from breast
cancer, could significantly influence our results.
Table II Tumour size by extreme quintiles ofQuetelet's index relative
to age at height and weight measurement
Tumour sizea
Quetelet's index To T, T2 T3 Sum
Quintile 1 0 42 13 0 55
Quintile 5 2 26 23 2 53
aAccording to the TNM classification (UICC, 1968).
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Figure 2 A comparison of survival rates of lowest (Q1) and
highest (Q5) quintile of relative Quetelet's index within stage of
breast cancer at diagnosis and by age-groups 30-49 years (a),
50-64 years (b), and 65 + years (c). The height parameter
(nk) = 1.00.
Table III Number ofpatients needed per year ofinclusion and size of
background breast cancer population by four different designs of an
intervention trial
Number ofpatients Size ofthe
neededper year of background breast
Design inclusion cancerpopulation
(a) Stage II patients,
1 year of inclusion,
5 years of follow-up. 900 17,000
(b) Stage I and II patients,
1 year of inclusion,
5 years of follow-up. 1,880 14,690
(c) Stage II patients,
3 years of inclusion,
3-5 years of follow-up 365 6,800
(d) Stage I and II patients,
3 year of inclusion,
3-5 years of follow-up. 750 5,860
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A high Quetelet's index was associated with a poorer
prognosis. This is in accordance with previous studies by
Boyd et al. (1981), Newman et al. (1986) and Hebert et al.
(1988). Tartter et al. (1981) and Greenberg et al. (1985)
reported that patients with high Quetelet's index fare worst,
but their results were not statistically significant. However,
they found a significant relationship between overweight and
bad prognosis. The prognostic effect of Quetelet's index in
this study is present only in stages I and II, which comprise
81% of all our cases. The highest risk is seen among patients
belonging to the highest quintile of the distribution
of Quetelet's index. For stage III and IV (13% of the
patients) no prognostic effect of Quetelet's index could be
seen. This is in accordance with Boyd et al. (1981) who
concluded that the prognostic effect was generally most
marked in patients with a tumour the prognostic characteris-
tics of which were favourable. Similar findings were reported
by Newman et al. (1986) and Hebert et al. (1988) and by
Donegan et al. (1978) who included weight but not Quetelet's
index in the analysis. Hebert et al. explained why the effect of
overweight is seen among women with early-stage disease by
the fact that the effect of overweight is more strongly ex-
pressed against the background of a set of relatively weaker
prognostic factors.
Another explanation may be that the staging was faulty.
Staging is a type of elimination procedure. Stage IV patients
and also the majority of patients in stage III have clear
diagnostic characteristics. All patients who do not fulfil the
criteria for stages III or IV will be in stage II if positive
lymph nodes are found and in stage I if not. If there are
circumstances connected to overweight women that make the
staging procedure more difficult, for example, if it was more
difficult to find regional lymph nodes or distant metastases,
then the stage classification will be too low which will result in
a spurious prognostic effect of overweight. For example, if
about 15% of the stage I patients in the highest quintile-group
of Quetelet's index were really in stage II and about 20% of
the stage II patients in the highest quintile group were stage
IV patients, this could explain approximately the observed
prognostic effect of being in the highest quintile group of
Quetelet's index. It seems improbable that the diagnostic
problems connected with overweight are of such a magni-
tude.
A third explanation may be, at least in part, that in
overweight women the tumour is larger because of a diagnos-
tic delay resulting in a worse prognosis. Among stage I
patients we found that the tumour size is larger among obese
than among leaner women. This is in accordance with the
results shown by Verreault et al. (1989). Unfortunately, it is
not possible to ascertain the tumour size as a variable in our
analysis. However, this has been done by Boyd et al. (1981).
They found that the prognostic effect of weight could not be
explained by differences in clinical stage using the TNM
classification (UICC, 1986) or histological grade of the
tumour. This indicates that the effect of obesity on breast
cancer prognosis is not an artefact of delayed diagnosis in
overweight patients. Another support for this statement is
given by Verreault et al. (1989). They found among patients
with oestrogen receptor positive tumours the percentage with
involved nodes at diagnosis increased with increasing
Quetelet's index after adjustment for tumour size. There was
no, or little, association between Quetelet's index and oestro-
gen receptor status or with any of the measured histological
features of the breast tumour like mitotic activity and nuclear
size.
While previous studies have computed Quetelet's index on
the basis of patients' weight at the time of diagnosis, this
study is based on height and weight measurement prior to
the diagnosis. However, the similarity between our results
and those from previous studies indicate that the time of
height and weight measurements has little effect on the pat-
tern of association. This is confirmed by our finding that the
prognostic effect of premorbid body mass index did not
depend on the length of time between measurement and
diagnosis.
Age was found to be a prognostic factor for breast cancer
patients in stages I and II. From a statistical point of view,
the absence of the effect of age in stages III and IV can by
chance be a result of small numbers. However, the same
observation was made in previous studies at the Cancer
Registry of Norway (1980) and the explanation may be that
women diagnosed in stage III and especially in stage IV are
in such a serious condition that the age is of minor impor-
tance for the outcome of the disease. Subgroup analysis by
age revealed that overweight is a prognostic factor both in
pre- as well as post-menopausal age. This is partly in contrast
with the conclusions of Boyd et al. (1981) who found that the
effect was most marked in post-menopausal women. This
disagreement may be caused by differences in the definition
of overweight. We think that a woman's body mass changes
with age, not only because of change in caloric intake or
physical activity. Our definition is therefore a consequence of
this view.
Wynder and Cohen (1982) discussed in an editorial the
rationale of dietary intervention in the treatment of post-
menopausal breast cancer patients. They suggested a ran-
domised prospective clinical trial with the control group
consuming their customary diet and the experimental group a
modified diet based on the Japanese model. They also sug-
gested that the trial group should be limited to post-meno-
pausal patients in stage II, because this subgroup has been
shown to be most resistant to chemotherapy. Our study
supports the findings that the prognostic effect expressed as
the absolute difference in survival between the lowest and
highest quintile is largest for patients in stage II, but the
results do not indicate that the trial group should necessarily
be restricted to post-menopausal women. Since the relative
prognostic effect is greatest for patients in stage I and they
represent about 50% of all breast cancer patients, the in-
clusion of these patients in the trial group should be dis-
cussed.
Our study indicates that in a possible dietary intervention
trial we should use our resources mainly on women belong-
ing to the fifth quintile of Quetelet's index relative to their
age. Dietary intervention should make breast cancer patients
in the fifth quintile lose weight down to the level of those in
the fourth quintile. That means a weight reduction of
8- 1O kg. For example, a 60-year-old woman, 160 cm tall,
having a Quetelet's index of 3.25 gcm-2, has to slim down
from 83.2 kg to 75.5 kg.
The feasibility of an intervention trial depends on the
possibility to include enough patients and to obtain enough
resources to slim down the women by about 10% of their
weight and to keep them at that level of weight. In Table III
it is demonstrated that a trial based on one year's inclusion
of patients in stage II (design a) would require 900 patients
from a background breast cancer population of minimum
17,000 cases (All ages). This illustrates the amount of resources
needed to carry out a trial with a reasonable precision. If the
trial group includes patients in stage I as well as stage II
(design b), then the number of patients needed will be
doubled, while the minimum size of the background breast
cancer population would decrease to 14,690. This means that
in designs (a) and (b) the minimum number of patients in the
background breast cancer population are about the same
size, while the need of resources will be doubled by using
design (b) instead of design (a). There may be other designs
than those mentioned here, but these examples may illustrate
the scope for such a trial.
As mentioned, Verreault et al. (1989) found that the
percentage of patients with involved lymph nodes at diag-
nosis increased significantly with overweight. This was true
mainly for women with a positive oestrogen receptor status.
An implication of this observation could be that overweight
is only a prognostic factor for patients having a positive
oestrogen receptor status. We have no data to examine this
hypothesis, but if this is true, it might be possible to define a
subgroup where overweight as a prognostic factor would be
even stronger than demonstrated in our study.HEIGHT-WEIGHT AND SURVIVAL OF BREAST CANCER 303
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